Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
Soligenix Inc (NASDAQ: SNGX) shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
根據Benzinga Pro的數據，納斯達克（NASDAQ: SNGX）的Soligenix公司股票週二成交量高達2360萬，股價大漲。
The Princeton, New Jersey-based company announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended Hybryte treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL).
這家總部位於新澤西州普林斯頓市的公司宣佈了關於開放標籤、研究者發起的研究的中期更新。該研究評估了早期切除性T細胞淋巴瘤（CTCL）患者在長達12個月時間內進行Hybryte治療的情況。
To date, six patients have been enrolled and treated with HyBryte for up to 44 weeks.
到目前爲止，已有六名患者接受了長達44周的HyBryte治療。
Patients have responded positively to HyBryte therapy. Three of the four subjects who have completed at least 12 weeks of therapy already achieved "Treatment Success."
患者對HyBryte治療作出了積極的反應。至少接受了12周治療的四名受試者中的三名已經實現了“治療成功”。
Two of the three Treatment Successes were achieved within the first 12 weeks of treatment, and the third within 18 weeks.
三項成功治療中，有兩例在12周治療內實現，第三例在18周內實現。
Two of the remaining three patients have only recently started HyBryte therapy. They have not yet reached their first efficacy evaluation visit (i.e., at Week 6). The other had a substantial improvement documented at the Week 18 visit but has not achieved the success threshold yet.
剩下的三名患者中，有兩名剛剛開始接受HyBryte治療，尚未到達首次療效評估的時間（即第6周）。另一名患者在第18周的時候記錄到有明顯改善，但尚未達到成功閾值。
In addition, HyBryte appears to be safe and well tolerated in all patients, with no treatment-related adverse events.
此外，所有患者都表現出HyBryte的安全性和耐受性，沒有發生治療相關的不良事件。
"In the Phase 3 FLASH study, HyBryte was shown to be efficacious with a promising safety profile. With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments.
在第3期FLASH研究中，HyBryte被證明具有良好的療效和安全性。早期CTCL患者的治療選擇有限，通常在尋求替代治療方法。
Initial results evaluating the expanded use of HyBryte in a "real world" treatment setting were "promising." This supports and extends results from the previous positive Phase 2 and 3 clinical trials.
在擴大使用HyBryte的"真實世界"治療的初步結果是“有希望的”，這與之前的陽性2期和3期臨床試驗的結果相一致。
"We look forward to continuing to work with the FDA to complete this study and to participating in the upcoming confirmatory Phase 3 placebo-controlled study," noted a principal investigator of the IIS.
該研究的主要研究員表示：“我們期待着繼續與FDA合作完成該研究，並參與即將到來的確認性第3期安慰劑對照研究。”
Recently, Soligenix released clinical results from a comparability study evaluating HyBryte versus Valchlor (mechlorethamine gel).
最近，Soligenix發佈了一項比較研究的臨床結果，評估HyBryte與Valchlor（癌特寧凝膠）的比較。
The open-label study (protocol HPN-CTCL-04) enrolled ten patients.
這項開放標籤的研究（HPN-CTCL-04協議）招募了10名患者。
The study revealed that HyBryte treatment resulted in 60% of patients achieving a 50% or better improvement in their mCAILS score versus 20% of Valchlor patients. HyBryte has a more favorable safety profile.
該研究顯示，HyBryte治療導致60%的患者的mCAILS得分提高了50%或更多，相比之下，Valchlor只有20%的患者達到該標準。HyBryte具有更良好的安全性。
Price Action: SNGX shares are up 221.5% at $6.43 at last check Tuesday.
截至週二最後一次查詢，SNGX股價上漲了221.5%，達到6.43美元。
Now Read:
現在閱讀：
- Curaleaf And Trulieve's Q2 Earnings — When Are The Cannabis Giants Reporting?
- Curaleaf和Trulieve的Q2業績——這些大麻股票巨頭何時公佈業績？
譯文內容由第三人軟體翻譯。